Alnylam Pharmaceuticals develops and commercializes drugs using RNA interference technology to treat genetic and metabolic diseases across multiple therapeutic areas including amyloidosis, liver disease, neurological disorders, and blood disorders. The company markets six approved medications and maintains an extensive pipeline of candidates in various clinical trial stages, from Phase 1 through Phase 3, alongside partnerships with major pharmaceutical firms. Founded in 2002 and based in Cambridge, Massachusetts, the company operates internationally with a focus on rare and severe conditions.

entry readiness 70 · GOOD SETUP · exit proximity 0

Value area 197.23–288.62 · 100% of 120d volume overhead · heavy supply

ALNY is a genuinely divided dossier: strong fundamentals (77) and a large earnings surprise collide with a broken tape (technical 7, Markov DOWN with 89% persistence) and a WEAKENING biotech complex. The daily lane itself resolves this by calling WATCH at 0% size — entry zone but setup unconfirmed — which is the honest read. Until the technical picture turns, the fundamental case has no trigger.

Invalidated if: A daily-lane flip from WATCH to OPEN on a confirmed entry trigger (or the Markov state turning UP) would make this cautious-neutral read wrong; a close that extends the downtrend confirms it.